• Sonoma Pharmaceuticals Inc SNOA.OQ reported a quarterly adjusted loss of 63 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.60. The lone analyst forecast for the quarter was for a loss of 69 cents per share.

• Revenue rose 13.6% to $3.56 million from a year ago; analysts expected $4.06 million.

• Sonoma Pharmaceuticals Inc's reported EPS for the quarter was a loss of 63 cents​.

• The company reported a quarterly loss of $928 thousand.

• Sonoma Pharmaceuticals Inc shares had fallen by 1.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 13.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "strong buy"

Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $17.00

This summary was machine generated from LSEG data February 6 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)